LDHA and non-small cell lung carcinoma: The Wnt pathway ligand, Wnt5a, can increase the stem properties of ALDH+ CSCs in cisplatin-resistant NSCLC (66), suggesting that Wnt signaling is a mechanism that mediates the resistance of NSCLC CSCs to chemotherapies.